Physician profile
Clara Hwang
NPI 1407978505
$15,938.24
in general payments reported to CMS, 2019-2025
20 companies · $4,906 in 2025
The $4,906 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $5,273 · 2021: $61.87 · 2023: $3,684 · 2024: $1,677 · 2025: $4,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,903 · Travel and Lodging: $3,952 · Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,902.50 |
| Travel and Lodging | $3,952.20 |
| Food and Beverage | $1,411.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $3,951.00 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $3,758.59 | 2020-2025 | |
| Exelixis INC. | $2,226.55 | 2023 | |
| Astellas Pharma Global Development | $1,875.00 | 2025 | Xtandi |
| Janssen Scientific Affairs, LLC | $1,782.70 | 2025 | Erleada |
| Janssen Biotech, INC. | $1,362.50 | 2023 | |
| Dendreon Pharmaceuticals LLC | $283.46 | 2019-2025 | Provenge |
| Merz North America, INC. | $190.64 | 2025 | |
| Pfizer INC. | $135.00 | 2024 | |
| Telix Pharmaceuticals | $132.50 | 2025 | Illuccix |
| E.R. Squibb & Sons, L.L.C. | $111.03 | 2019 | |
| Genentech, INC. | $57.41 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $54.57 | 2023 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $17.29 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.